• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Titan Pharmaceuticals lands $10m debt facility

July 31, 2017 By Sarah Faulkner

Titan PharmaceuticalsTitan Pharmaceuticals (NSDQ:TTNP) said last week that it inked a $10 million venture loan and security deal with Horizon Technology Finance Corp.

The first $7 million tranche was triggered after the groups inked a deal, Titan reported, and a second option of $3 million is available to the California-based company until March 31, 2018, contingent upon certain revenue and development milestones.

According to the deal, Titan issued warrants to Horizon to buy an aggregate of 280,612 shares of common stock at $1.96 apiece. The company also issued Horizon a warrant to be exercised upon the funding of the loan’s second tranche.

“We believe this transaction balances our capital needs and opportunity to grow the company, and our commitment to minimizing dilution for shareholders to the extent possible,” Titan President and CEO Sunil Bhonsle said in prepared remarks. “We were impressed with Horizon’s ability to tailor a financing structure that matched Titan’s objectives. We expect that our existing cash on hand, combined with the net proceeds from the first tranche of this loan, will be sufficient to fund planned operations into early 2019.”

The loan agreement, which has a term of 46 months, consists of interest-only payments through the end of 2018. The initial interest rate was set at 9.63% and each loan tranche is subject to a 5% final payment when the principal is paid in full, according to the deal. The senior debt is secured by all of Titan’s assets, except for its IP, the company reported.

“We are pleased to provide this debt financing to Titan. The company’s proprietary long-term drug delivery platform, ProNeura, represents a new standard of chronic disease management utilizing subdermal implants,” Horizon president Gerald Michaud added. “We look forward to working with Titan as its lead product, Probuphine, advances in the marketplace and the company continues to develop a growing pipeline of new treatments for select therapeutic markets.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS